Chryscandin is a peptidyl nucleoside antibiotic ( Fig. 1 ), isolated from a strain of fungi Chrysosporium pannoruml1), and inhibited the growth of Candida albicans. The chemical structure and total synthesis of the antibiotic have been elucidated2, 3, 4) . Concerning the chemical structure, chryscandin resembles puromycin5), the biological properties, however, differ from those of puromycin6'7~. That is, the former possesses an activity against Candida and has a low toxicity, whereas the latter shows candin and/or by replacing an R group in the 3'-aminoacyl side chain of chryscandin.
Chemistry
Chryscandin is composed of three parts, a base (adenine), a sugar (aminoribofuranuronic acid)
and an amino acid (O-methyl-L-tyrosine). First of all, therefore, it is considered important to grasp their effects on the anti-yeast activity: (1) With regard to the adenine base, when either the adenine was exchanged for a uracil (92 and 93) or the primary amino group located on adenine was substituted by C6H5CH.,CHNH.,
an N-methyl amino, N,N-dimethyl amino, hydroxyl and methoxy, respectively, no activity was found in any case (94-97).
Therefore, adenine nucleus seemed to be an essential moiety. (2) Amidation of the carboxyl group (68 -71 and 85 -91) or etherification of the hydroxyl group (98 and 99) on the aminoribofuranuronic acid resulted in little activity against Candida. These facts show that these particular functional groups play an important role in its biological activity. (3) Subsequently, it was observed that the anti-yeast property was completely destroyed by removing the aminoacyl side chain of chryscandin with alkaline solution. However, its biological activity was regenerated by introducing another acyl group, which resulted in more potent activity than native chryscandin in some cases (16-19, 21-23, 25, 26, 29, 31, 39 -41, 47 and 77) . It is suggested that the O-methyl-L-tyrosyl moiety is not required for activity at the target site, but it probably effects penetration. Thus, our efforts were mainly directed at elucidating the effects of the acyl group of adenyl-3'-acyl aminoribofuranuronic acid (Tables 1-3) .
The starting material, 3-amino-l-(6-benzoylamino-9H-purin-9-yl)-1,3-dideoxy-f3-D-ribofuranuronic acid (I) (Fig. 2) , of the series was prepared as previously reported3' 4' from D-xylose and N6-benzoyladenine in nine steps. Condensation of I with an active ester of the N-protected amino acid, in the presence of triethylamine, produced 1 ti 12 and 58 (Method 1). In order to protect the amino group benzyloxycarbonyl (Z) or tert-butoxycarbonyl (t-Boc) and, for activation of carboxylic acid, Nhydroxysuccinimide (HOSu) were used in the conventional manner. These protective groups were removed by the usual methods as shown in the Experimental section and Fig. 4 . N,N'-Dicyclohexylcarbodiimide (DCC) was applied to the condensation of methyl (or ethyl)-1-(6-amino-9H-purin-9-yl)- Both reactions of an amino acid with an active ester of chryscandin in the presence of triethylamine and hydrazine with methylester of chryscandin led to a 5'-substituted chryscandin, respectively (71, 86 and 91, and 68 -70) (Methods 6 and 7, respectively). For a 5'-substituted S-benzylcysteine, derivative of 16, its active ester was also used with some nucleophilic reagents (85 and 87-9O) (Method 8) (Fig. 3) . The structure of the resulting acylamino derivatives was confirmed by IR and iH NMR as shown in Table 4 .
Microbiology
The minimum inhibitory concentrations (MIC) of the synthesized compounds against C. albicans, Staphylococcus aureus 209P and Escherichia toll NIHJ are shown in Table 5 .
In this series, L-a-aminoacyl derivatives were prepared since 7, 58 and 78 including n-aminoacyl or 3 and 6 containing j3-and r -aminoacyl resulted in a greatly diminished activity against Candida.
In general, the compounds having /3-aryl-a-L-aminoacyl groups conferred superior activity against Candida to those having aliphatic a-L-aminoacyl (5 and 10) and a-aryl-a-L-aminoacyl groups (4 and 8). Furthermore, a series of a-L-aminoacyl analogs possessing S-alkyl cysteinyl moiety was prepared systematically on account of the high anti-candida activity of its members.
Taking these facts into consideration, a total of 99 compounds were prepared according to methods 1 -8 (Tables 1 3 and Chemistry) . Among them, some aminoalkanoyl derivatives having a cysteinyl exhibited two-to sixteen-fold enhanced anti-yeast activity compared with that of native chryscandin Table 6 . The efficacy of 16 was almost the same as that of 5-fluorocytosine and a superior to that of ketoconazole.
Experimental
Melting points were measured on a Yanagimoto microscope hot-stage apparatus and were not corrected. IR spectra were recorded on Jasco IRA-2 or Jasco A-102 spectrophotometer.
1H NMR spectra were recorded using Jeol PMX-60 or Jeol PS-100 spectrophotometer.
General Procedures for Removal of Protection Groups
Deprotection was carried out as follows. Debenzoylation : A suspension of a benzoylamino derivative (0.1 mmol) in a mixture of McOH (5 ml) and butylamine (2.3 ml) was boiled under reflux for 1 hour. The mixture was evaporated under reduced pressure. The residue was subjected to column chromatography on silica gel and eluted with a mixture of CHC13 -MeOH (7: 3) (Method A). Debenzyloxycarbonylation : A suspension of a derivative of N-benzyloxycarbonyl methyl ester (0.1 mmol) in H2O (80 ml) was adjusted to pH 3 with 1 N HCI. The resulting mixture was hydrogenated under medium pressure (3.0-3.5 atm) over palladium black (12 mg) for 3 hours. The catalyst was removed by filtration and the filtrate was adjusted to pH 7 with 1 N NaOH. The result- Table 5 . MIC values of chryscandin derivatives. ing mixture was concentrated under reduced pressure to a volume of 12 ml. The concentrate was applied to a column of non-ionic adsorption resin HP-20 (Mitsubishi Kasei, 20 ml) and the column was washed with H2O (40 ml) and then eluted with a mixture of MeOH -H2O (3:7, 40 ml) (Method B).
De-tert-butoxycarbonylation : A mixture of a tert-butoxycarbonylamino derivative (0.1 mmol) and formic acid (1 ml) was stirred for 2 hours at room temp and evaporated to dryness. The residue was dissolved in H2O (7 .5 ml) and adjusted to pH 7 with aq NaHCO3. The solution was subjected to column chromatography on the Diaion HP-20 (30 ml). After the column was washed with H 2O, the elution was carried out with 30% aq McOH (Method C). A mixture of a tert-butoxycarbonylamino derivative (0 .1 mmol) and anisole (0.1 ml) was stirred in an ice-bath , and TFA (1 ml) was added. After stirring for 1 hour in an ice-bath, Et2O was added to the mixture. The resulting precipitates were collected by filtration (Method D).
Deesterification : To the precipitates , 1 N NaOH (1 ml) was continuously added, and stirred for 30 minutes in an ice-bath. The reaction mixture was neutralized with 1 N HC1 , and subjected to the Diaion HP-20 column (Method E) (Fig. 4) .
Synthesis of 1. Method 1
To a stirred solution of N-benzoyloxycarbonyl-O-methyl-L-tyrosine (181 mg) and N -hydroxysuccinimide (HOSu) (64 mg) in dioxane (10 ml) was added N ,N'-dicyclohexylcarbodiimide (DDC) (114 mg) under cooling in an ice-bath. The mixture was stirred overnight at room temp . The suspension was filtered and the filtrate was evaporated to dryness in vacuo . The residue was dissolved in THE (5 ml) and the solution was added to a solution of 3-amino-l-(6-benzoylamino-9H-purin-9-yl)-1 ,3-did eoxy-19-D-ribofuranuronic acid (150 mg) and triethylamine (0 .08 ml) in H2O (5 ml). The mixture was stirred for a day at room temp. THE was evaporated in vacuo and the residual aq solution was adjusted to pH 2 with 1 N HCl and extracted with EtOAc (30 ml x 3) . The extracts were combined, washed with satd NaCI, dried over MgSO4 and evaporated to dryness in vacuo . The residue was subjected to column chromatography on silica gel and eluted with a mixture of CHCI . Th e fractions containing the object compound were combined and evaporated in vacuo to give 1 -(6-benzoylamino-9H-purin-9-yl) Method E NaOH NO. 9 THE JOURNAL OF ANTIBIOTICS prepared, mp, spectral data and antimicrobial activities of these compounds are shown in Tables 1 and 4 .
Synthesis of 16. Method 2 A mixture of ethyl-l-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-amino-l3-n-ribofuranuronate (308 mg), N-tert-butoxycarbonyl-S-benzyl-L-cysteine (311 mg) and DCC (206 mg) in THE (15 ml) and H2O (5 ml) was stirred overnight. The precipitates were removed by filtration. The filtrate was diluted with H2O (50 ml), extracted with EtOAc, washed with H2O and dried (Na2SO4). The solvent was removed in vacuo and the residue was subjected to column chromatography on silica gel. The elution was carried out with a mixed solvent CHC13 -MeOH (97: 3). The eluate was evaporated to dryness to give ethyl-1-(6-amino-9H-purin-9-yl)-1,3-dideoxy Table 4 . In a similar way, 17-47, 50 -57 and 59 -65 were prepared ( Table 2) .
Synthesis of 14. Method 3
To a mixture of 1 -(6-amino-9H-purin-9-yl)-1 ,3-dideoxy-3-amino-f3-D-ribofuranuronic acid monohydrate (149 mg) and triethylamine (0.21 ml) in H2O (5 ml) was added a solution of the N-hydroxysuccinimide ester of N-tert-butoxycarbonyl-S-phenyl-DL-cysteine in THE (5 ml) under stirring overnight at room temp. The reaction mixture was washed with Et20 and the remaining aq solution was adjusted to pH 2 with 1 N HCI. The resulting precipitates were filtered off, washed with H2O and dried in a desiccator to yield 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy Table 4 . According to a similar manner 15, 48, 49, 66, 67 and 77/%/ 84 were synthesized ( Table 1) .
Synthesis of 72. Method 4
To a mixture of 1-(6-benzoylamino-9H-purin-9-yl)-1,3-dideoxy-3-amino-j3-n-ribofuranuronic acid (384 mg) and triethylamine (0.35 ml) in H2O (10 ml) was dropped a solution of phenylacetyl chloride (0.171 g) in THE (10 ml) under cooling in an ice-bath and stirring, which was continued for 30 minutes at the same temp. The mixture was evaporated in vacuo and the remaining aq solution was washed with Et20 and acidified with 6 N HCI. The mixture was extracted with a mixture (80 ml) of EtOH -CHC13 (1: 1) and the extract was dried over MgSO4, evaporated and triturated with EtO to give 1-(6-benzoylamino-9H-purin-9-yl)-3-(phenylacetylamino) Table 4 . According to a similar manner 73-76 were prepared ( Table 1) The preparation methods of 92-97 were similar to that of chryscandin (Table 3) .
Synthesis of 98
Ethyl ester of II (2.80 g), N-carboethoxyphthalimide (2.39 g) and NaHCO, (764 mg) in 50% aq THE (56 ml) were stirred at room temp for 4 hours. The resulting precipitates were filtered off ,washed with 50% aq THE and dried in vacuo to yield as a colorless powder (2.51 g), ethyl 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-phthalimido-~3-D-ribofuranuronate, mp 248 N 251°C (dec); IR (Nujol) 3250, 3100, 1755, 1720, 1685, 1610, 1335 and 1210 cm-1; 1H NMR (DMSO-de) o 1.17 (3H, t, J=7 Hz), 4.18 (2H, q, J=7 Hz), 5.00' 5.40 (3H, m), 6.09 (1H, d, J=5 Hz), 6.33 (1H, d, J=6 Hz), 7.28 (2H, br s), 7.92 (5H, s), 8.12 (1H, s) and 8.45 (1H, s). To this compound (1.9 g) in DMF (15 ml) was added NaH (229 mg) under stirring and cooling in an ice-bath for 30 minutes. Furthermore, to the mixture was added MeI (0.81 ml) and stirring continued for 40 minutes. The reaction mixture was poured into 0.1 N HC1 (100 ml), adjusted to pH 2 with 2 N NaOH and then extracted with EtOAc (100 ml x 2). The extracts were combined, washed with H2O and satd NaCI, dried over MgSO4 and evaporated to dryness in vacuo. The residue was subjected to column chromatography on silica gel and eluted with a mixture of CHCl3 -EtOAc (3: 10). The fractions containing the object compound were combined and evaporated in vacuo to give as a colorless powder (158 mg), ethyl 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-2-O-methyl-3-phthalimido-J3-D-ribofuranuronate, mp 158 N 160°C (dec); IR (Nujol) 3300, 3150, 1740, 1660 and 1600 cm-1; 1H NMR (DMSO-d8 +D20) o 1.12 (2H, t, J=7 Hz), 3.12 (3H, s) This methyl ether (116 mg) was dissolved in THE (0.5 ml), added 1 M ethanolic hydrazine hydrate (0.257 ml) and stirred for 5 minutes at room temp. The solution was evaporated to dryness in vacuo. To the residue were added N-tent-butoxycarbonyl-S-methyl-L-cysteine (60.0 mg), DCC (79.0 mg), H2O (1.0 ml) and THE (5.0 ml), stirred for 8 hours at room temp. After filtration the solution was ex- 
